Vasoconstrictory thromboxane A2 and vasodilatory prostacyclin in climacteric women: effect of oestrogen-progestogen therapy.

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Maturitas

• Publication date

  1984-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0378-5122(84)90053-7PMID 6427552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of prostacyclin and thromboxane production by human umbilical vessels: the effect of estradiol and progesterone in a superfusion model.

  1982cited by this paper
• The effect of oral contraceptives on antiaggregatory prostacyclin and proaggregatory thromboxane A2 in humans.

  1982cited by this paper
• Plasma 6-keto-prostaglandin F1α: Fact or fiction

  1982cited by this paper
• Prostacyclin is not a circulating hormone in man.

  1982cited by this paper
• Plasma 6-keto-prostaglandin F1alpha: fact or fiction.

  1982cited by this paper
• Prostacyclin, thromboxane and prostaglandin F2 alpha in suction blister fluid of human skin: effect of systemic aspirin and local glucocorticosteroid treatment.

  1981cited by this paper
• Prostacyclin is not a circulating hormone.

  1981cited by this paper
• Postmenopausal estrogen therapy: a review.

  1981cited by this paper
• Effect of synthetic estrogen on platelet aggregation and vascular release of PGI2-like material in the rabbit.

  1980cited by this paper
• Prostacyclin-like activity in the female rat thoracic aorta and the inferior vena cava after ethinyloestradiol and norethisterone.

  1980cited by this paper
• Measurement of thromboxane B2 in human plasma or serum by radioimmunoassay.

  1980cited by this paper
• Enhanced prostacyclin formation in veins of women under chronical treatment with oral contraceptive drugs.

  1980cited by this paper
• Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls.

  1979cited by this paper
• Increased prostacyclin-like activity in vascular tissues from rats on long-term treatment with an oestrogen-progestagen combination.

  1979cited by this paper
• An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

  1976cited by this paper
• Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

  1975cited by this paper

• Postmenopausal hot flushes, vascular health and hormone therapy

  2010cites this paper
• Devamli kombine hormon replasman tedavisinin uterin perfüzyon ve endometrial kalinlik üzerine etkisinin uterin arter Doppler bulgulari ile değerlendirilmesi The effect of continuous hormone replacement therapy on endometrial thickness and uterine perfusion with Doppler sonography of the uterine arte

  2005cites this paper
• Pregnancy enhances the angiotensin (Ang)-(1-7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1-7).

  2003cites this paper
• Plasma cholesteryl ester fatty acid composition, insulin sensitivity, the menopause and hormone replacement therapy.

  2000cites this paper
• Monitoring of hormone replacement therapy in postmenopausal women by transvaginal sonography and color flow doppler: study in different phases of sequential therapy.

  1999cites this paper
• Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women.

  1997cites this paper
• Different Effects of Oral and Transdermal Hormonal Replacement on Prostacyclin and Thromboxane A2

  1997cites this paper
• Effects of estrogen replacement therapy on thrombin generation.

  1997cites this paper
• Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives.

  1995cites this paper
• Sex steroids, psychosocial factors, and lipid metabolism.

  1993cites this paper
• Estrogen: risk versus benefit for the prevention of coronary artery disease.

  1993cites this paper
• The role of reproductive hormones in vascular disease and hypertension.

  1993cites this paper
• HRT and osteoporosis.

  1993cites this paper
• The role of thromboxane in the uterotrophic response in the gravid normotensive and spontaneously hypertensive rat.

  1992cites this paper
• HRT: developments in therapy.

  1992cites this paper
• The role of progestins in hormone replacement therapy

  1992cites this paper
• Decreased Mortality in Users of Estrogen Replacement Therapy

  1991cites this paper
• Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: effect of estrogen-progestin replacement therapy.

  1990cites this paper
• Risks of estrogens and progestogens.

  1990cites this paper
• Oestrogen Replacement Therapy and Cardiovascular Disease

  1990cites this paper
• Risks and benefits of long-term treatment with estrogens.

  1989cites this paper
• Dermal prostacyclin, thromboxane A2 and prostaglandin F2 alpha in climacteric women: effect of oestrogen replacement therapy.

  1986cites this paper
• Progestogens and lipid metabolism.

  1986cites this paper
• Prostacyclin and thromboxane in gynecology and obstetrics.

  1985cites this paper